NeuroSense Therapeutics Ltd. Warrant (NRSNW)
Official siteBIOTECHNOLOGY • NASDAQ
Last updated: Nov 16, 2026 at 4:00 PM ET
Earnings
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 78.0% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 36.2, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about NRSNW
News
No news available
Company news will appear here when available
NRSNW Valuation
- P/B
- -0.0x
NRSNW Profitability: Margins, ROIC and FCF
NeuroSense Therapeutics Ltd. Warrant (NRSNW) has an operating margin of 0.0% and a net margin of 0.0%.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -2175.0%
NeuroSense Therapeutics Ltd. Warrant Competitors
The companies most similar to NeuroSense Therapeutics Ltd. Warrant (NRSNW) include Sionna Therapeutics, Inc. Common Stock, Neurogene and ProMIS Neurosciences.
Sector: Healthcare
Updated Oct 25, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About NRSNW
Does NRSNW pay dividends?
NeuroSense Therapeutics Ltd. Warrant (NRSNW) does not currently pay a regular dividend.
NRSNW pages: Overview, Financials
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.